Navigation Links
Aeterna Zentaris to Raise US$12 Million in Registered Direct Offering
Date:6/15/2010

QUEBEC CITY, June 15 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, announced today that it has received commitments from institutional investors to purchase US$12.1 million of securities in a registered direct offering. Under the terms of a Securities Purchase Agreement, the Company will sell to such institutional investors an aggregate of approximately 8.8 million common shares of its capital at a price of US$1.3725 per share and issue warrants to acquire an aggregate of approximately 4.4 million common shares at an exercise price of US$1.3725 per share.

The warrants to purchase additional common shares of Aeterna Zentaris will be exercisable immediately upon issuance and will expire on the fifth-year anniversary thereof. All of the securities were offered pursuant to an effective shelf registration statement filed in the United States. Proceeds from the transaction will be used to fund the Company's AEZS-108, AEZS-112 and AEZS-130 programs and for other general corporate and working capital purposes. The offering is expected to be consummated no later than June 18, 2010, subject to customary closing conditions.

Rodman & Renshaw, LLC, a subsidiary of Rodman & Renshaw Capital Group, Inc., (NASDAQ: RODM), acted as the exclusive placement agent for the transaction.

The proceeds from Aeterna Zentaris' registered direct offering that was completed on April 20, 2010 have been and a
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Aeterna Zentaris Receives Positive Opinion for Orphan Medicinal Product Designation for AEZS-108 for the Treatment of Ovarian Cancer from the Committee for Orphan Medicinal Products of the European Medicines Agency
2. Aeterna Zentaris Reports First Quarter 2010 Financial and Operating Results
3. Aeterna Zentaris: FDA Approves Investigational New Drug (IND) Application for Doxorubicin Targeted Conjugate Compound, AEZS-108, in Bladder Cancer
4. Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer
5. AEterna Zentaris Announces Termination of Agreement with sanofi-aventis U.S. for the Development, Commercialization and Licensing of Cetrorelix in Benign Prostatic Hyperplasia
6. AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
7. AEterna Zentaris Announces Appointment of New Board Member
8. AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
9. AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia
10. AEterna Zentaris Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma
11. AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... On September 11, Pharma IQ conducted an interview ... a session that he will lead on “Stem Cells” at ... 17-18, 2015 in London. In the interview posted ... to respond to several questions on the current state of ... cell toxicity, and future trends in the use of stem ...
(Date:9/29/2014)... CA (PRWEB) September 30, 2014 ... million burn injuries require medical attention. In the ... brings serious complications to battlefield medical care. More ... Iraq and Afghanistan. Burn wounds heal slowly, remain ... can be excessive, physically debilitating and functionally damaging. ...
(Date:9/29/2014)... TORONTO , Sept. 29, 2014 /PRNewswire/ - Portage Biotech ... Exchange: PBT.U), is pleased to announce that its three ... of Portage, who advanced $ 100,000 each in July ... have their Notes and related Coupons converted into 3,500,001 ... and carried 5% coupon. Both the Note and the ...
(Date:9/29/2014)... 29, 2014 Transparency Market Research, in ... SPPS, LPPS, HPPS, by Application - Cancer, Metabolic, CVS, ... and by Delivery) - Global Industry Analysis, Size, Share, ... the global peptide therapeutics market was worth US$14.1 billion ... by 2018 at an 8.7% CAGR. , The two ...
Breaking Biology Technology:Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 2Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 3Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 4Faster Healing with Fewer Scars 2Portage announces conversion of its debt into equity 2Portage announces conversion of its debt into equity 3Global Peptide Therapeutics Market to be Worth US$25.4 Billion by 2018: Transparency Market Research 2Global Peptide Therapeutics Market to be Worth US$25.4 Billion by 2018: Transparency Market Research 3
... Calif., Jan. 21 VNUS(R) Medical,Technologies, Inc. (Nasdaq: ... minimally invasive treatment of peripheral vascular disease,announced today that ... quarter ended December 31, 2007, after the close of ... regular quarterly teleconference at 2:00 p.m. PT,/ 5:00 p.m. ...
... Two Development Milestones in its Ofatumumab ... Collaboration With GlaxoSmithKline., COPENHAGEN, January 21 ... second and third development milestones,for ofatumumab (HuMax-CD20(R)) under the terms ... of the collaboration of DKK 87.2 million,was triggered by treatment ...
... company insiders knowingly misrepresented the ... ... Sobol Shapiro filed a,proposed class-action lawsuit on behalf of CellCyte ... the company and chief executive officer Gary A.,Reys, background, causing ...
Cached Biology Technology:VNUS Medical Technologies to Report Fourth-Quarter 2007 Results and Webcast Teleconference on February 7 2Genmab Reaches Milestones in Ofatumumab Collaboration 2Genmab Reaches Milestones in Ofatumumab Collaboration 3Hagens Berman Sobol Shapiro: Lawsuit Filed Against CellCyte Genetics Corporation 2Hagens Berman Sobol Shapiro: Lawsuit Filed Against CellCyte Genetics Corporation 3
(Date:9/30/2014)... 30, 2014  Spectra Automation, a trusted ... biotech and power generation industries, announced today ... Manager, an easy-to-use and cost-effective data collection, ... development laboratories. Most upstream ... analyzer systems. Accessing and consolidating data from ...
(Date:9/29/2014)... called Clostridium ramosum , coupled with a high-fat diet, ... this week in mBio , the online open-access journal ... team from the German Institute of Human Nutrition Potsdam-Rehbruecke in ... C. ramosum gained weight when fed a high-fat diet. ... less obese even when consuming a high-fat diet, and mice ...
(Date:9/29/2014)... story from 2009, "human activities in this area of the ... oil is increasingly grown for use as a cooking oil ... It has become the most widely produced edible oil in ... surpass that of soybean oil. , The environmental effects of ... to grow the crop, and the preferred method is fire. ...
Breaking Biology News(10 mins):Spectra Automation Introduces RECONN Bioprocess Manager 2Gut bacteria promote obesity in mice 2
... 2013 UT Southwestern Medical Center researchers report that ... to inflammatory disease, indicating that the production of a ... clock. The study published in the Nov. 8 ... pathway by which the body,s circadian clock controls the ...
... Science Foundation (NSF), in cooperation with interagency and ... awards under a program that supports multi- and ... and sustainability of the natural and living environment, ... the Arctic. Six projects have been ...
... URBANA, Ill. Despite a 12-year action plan calling for ... progress has been made, and there is no evidence that ... University of Illinois researchers have identified some of the biophysical ... "We are suggesting that a partnership of researchers work ...
Cached Biology News:UT Southwestern researchers identify how body clock affects inflammation 2UT Southwestern researchers identify how body clock affects inflammation 3NSF, with interagency and international partners, makes first round of grants to understand Arctic sustainability 2NSF, with interagency and international partners, makes first round of grants to understand Arctic sustainability 3NSF, with interagency and international partners, makes first round of grants to understand Arctic sustainability 4NSF, with interagency and international partners, makes first round of grants to understand Arctic sustainability 5NSF, with interagency and international partners, makes first round of grants to understand Arctic sustainability 6Researchers suggest plan to address hypoxia in Gulf of Mexico 2Researchers suggest plan to address hypoxia in Gulf of Mexico 3